CELLO Study for Radiologically Isolated Syndrome (RIS)
Diseases of the Nervous System
What is the purpose of this trial?
Do you have a close family member with Multiple Sclerosis (MS)? Have you ever wondered if you are at risk for developing MS? You may be eligible to participate in a research study.
Radiologically isolated syndrome (RIS) is diagnosed when someone is discovered to have brain MRI abnormalities that look like MS, but they have never had symptoms of MS. Many people diagnosed with RIS ultimately develop MS. The CELLO clinical trial is examining whether shortterm use of ocrelizumab, an immune modulating medication used to treat MS, can prevent MS brain abnormalities and/or MS symptoms from developing in people with RIS.
You may be eligible to participate in the CELLO study if you:
- Have been diagnosed with radiologically isolated syndrome
- Are between age 18 and 40
If you have not been diagnosed with RIS, but are a close family member of someone with MS and would like to participate in the study, we can test you for RIS as part of the study. Testing would involve getting an MRI of the brain. CELLO study participants would complete study visits over 4 years and donate biospecimens including blood, mouth swabs, and spinal fluid. Compensation is provided.
- Ages18 years - 40 years
- Trial withYale University School of Medicine
- Start Date05/12/2022
- End Date07/31/2028
- Last Updated08/02/2022
- Study HIC#2000029952